Cariprazine: all 53 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With SchizophreniaNot yet recruitingNCT07722728Phase 2/3
• Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in SchizophreniaNot yet recruitingNCT07715253Phase 1
• RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)RecruitingNCT07266545Phase 4
• Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral CariprazineRecruitingNCT07185815Phase 1/2
• Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive DisorderNot yet recruitingNCT05933538Phase 4
• Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)RecruitingNCT05913947Phase 4
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.RecruitingNCT04777357Phase 3
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaRecruitingNCT03817502Phase 3
• Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaTerminatedNCT05368558Phase 3Results posted
• The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneCompletedNCT03739203Phase 3Results posted
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneCompletedNCT03738215Phase 3Results posted
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaTerminatedNCT03593213Phase 3Results posted
• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed FeaturesCompletedNCT03573297Phase 3Results posted
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I DepressionCompletedNCT02670551Phase 3Results posted
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I DisorderCompletedNCT02670538Phase 3Results posted
• Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive DisorderCompletedNCT01838876Phase 3Results posted
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)CompletedNCT01715805Phase 3Results posted
• A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs SchizophreniaCompletedNCT01626885Phase 2/3Results posted
• Long-Term Study of MP-214 in Patients With SchizophreniaCompletedNCT01626872Phase 2/3Results posted
• A Pharmacokinetic Study of MP-214 in Patients With SchizophreniaCompletedNCT01626859Phase 2/3Results posted
• A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly SchizophreniaCompletedNCT01625897Phase 2/3Results posted
• Safety and Efficacy of MP-214 in Patients With SchizophreniaCompletedNCT01625000Phase 2/3Results posted
• Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderCompletedNCT01469377Phase 2Results posted
• A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaCompletedNCT01412060Phase 3Results posted
• Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar DepressionCompletedNCT01396447Phase 2Results posted
• Long-term Study of Cariprazine in Patients With SchizophreniaCompletedNCT01104792Phase 3Results posted
• Safety and Efficacy of Cariprazine in SchizophreniaCompletedNCT01104779Phase 3Results posted
• Safety and Efficacy of Cariprazine in Patients With SchizophreniaCompletedNCT01104766Phase 3Results posted
• Long-term Safety and Tolerability of Cariprazine for Bipolar I DisorderCompletedNCT01059539Phase 3Results posted
• Safety and Efficacy of Cariprazine for Bipolar I DisorderCompletedNCT01058668Phase 3Results posted
• Safety and Efficacy of Cariprazine for ManiaCompletedNCT01058096Phase 3Results posted
• Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With SchizophreniaCompletedNCT00862992Phase 2Results posted
• Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive DisorderCompletedNCT00854100Phase 2Results posted
• Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar DepressionCompletedNCT00852202Phase 2Results posted
• A Study of Cariprazine in Patients With Chronic Stable SchizophreniaCompletedNCT00839852Phase 2Results posted
• Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of SchizophreniaCompletedNCT00694707Phase 2Results posted
• Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute ManiaCompletedNCT00488618Phase 2Results posted
• Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)CompletedNCT07691190Phase 1
• Bioequivalence Assessment Between Two Cariprazine Hard Capsule FormulationsCompletedNCT07121868Phase 1
• Sequential Multiple Assignment Randomized Trial for Bipolar DepressionActive, not recruitingNCT06433635Phase 4
• Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASDCompletedNCT05439616Phase 3
• Cariprazine Versus Placebo for Social Anxiety DisorderCompletedNCT05384483Phase 4
• Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With SchizophreniaStatus unknownNCT05168007Phase 3
• Cariprazine for Comorbid Cocaine and Opioid Use DisorderCompletedNCT05063201Phase 2
• Dopamine D3 Receptor Occupancy in Bipolar DepressionWithdrawnNCT05060549Phase 4
• A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs AloneWithdrawnNCT04965272Phase 2
• Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity DisorderStatus unknownNCT04843423Phase 4
• Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar PatientsTerminatedNCT04771299Phase 3
• Cariprazine Pediatric ASD PK StudyCompletedNCT04382885Phase 1
• Cariprazine Effects on Brain and Behavior in Cocaine Use DisorderTerminatedNCT03430544Phase 2
• Cariprazine: Comparison of Slow- and Immediate-release FormsCompletedNCT02165098Phase 1
• Effects of Cariprazine on Cardiac Repolarization in Patients With SchizophreniaCompletedNCT01376076Phase 1
• Study Evaluating RGH-188 in the Treatment of Patients With SchizophreniaCompletedNCT00404573Phase 2

← Cariprazine overview